Advanced HF in Finland: Costs, Survival Diverge for Elective vs Urgent LVAD

Why It Matters

The findings highlight that elective LVAD or transplant provide cost‑effective, high‑survival options, while urgent LVAD incurs higher expenses and poorer outcomes, informing resource allocation and patient selection in heart‑failure care.

Key Takeaways

• Elective LVAD and transplant show similar 24‑month survival
• Urgent LVAD after ECMO yields 62% survival, higher costs
• Median urgent LVAD cost €293k, exceeds elective €188k
• ICU stay median 5 days elective, 20.5 days urgent
• Results guide patient selection in publicly funded systems

Pulse Analysis

Finland’s universal health‑care model offers a unique lens on advanced heart‑failure therapy, where both heart transplantation and elective left ventricular assist device (LVAD) implantation are fully reimbursed. The study examined 78 patients between 2022 and 2025, revealing that elective LVAD recipients achieved a 93.4% 24‑month survival rate, closely matching the 84‑100% survival seen in transplant cohorts. Importantly, the cost profile for these elective pathways clustered around €187,000‑€208,000 per patient in the first three months, underscoring their economic parity within a publicly funded framework.

When patients required urgent LVAD placement after failing extracorporeal membrane oxygenation (ECMO), outcomes diverged sharply. Survival dropped to 62.5% at two years, and median expenses surged to €293,355—significantly higher than elective options. The urgent group also endured longer intensive‑care stays (median 20.5 days versus 5 days), extended ventilation, and a five‑fold increase in dialysis use. These clinical and financial burdens illustrate how acute instability amplifies both risk and resource consumption, challenging hospitals to refine criteria for emergent mechanical support.

The broader implication extends beyond Finland. Health systems with centralized transplant programs and comprehensive reimbursement can leverage these real‑world data to prioritize elective LVAD placement before patients deteriorate to ECMO‑dependent shock. While the sample size remains modest, the trend suggests that early intervention may optimize both survival and cost‑effectiveness. Future research should expand cohort sizes, incorporate newer LVAD technologies, and compare outcomes across differing payer models to validate the generalizability of these findings.